1.10 Hypertensive Crises & Dyslipidemia
Key Takeaways
- Lipid disorders appear as a named subsection under both Cardiovascular Disease and Endocrinology, Diabetes, and Metabolism.
- Hypertensive emergency requires acute target-organ damage; the same blood pressure without organ injury is urgency and is managed with oral agents.
- Mean arterial pressure should be reduced by no more than approximately 25% in the first hour in most hypertensive emergencies to avoid cerebral and renal hypoperfusion.
- Aortic dissection and eclampsia are exceptions requiring rapid reduction to a specified systolic target rather than a graded 25% reduction.
- Ezetimibe and PCSK9-directed therapy are added to maximally tolerated statin therapy in very high-risk atherosclerotic disease when LDL cholesterol remains above threshold.
Last updated: August 2026
1. Hypertensive Crises: Urgency vs. Emergency
A hypertensive crisis is defined as a severe acute elevation in blood pressure, typically Systolic BP >= 180 mmHg and/or Diastolic BP >= 120 mmHg.
Hypertensive Urgency vs. Hypertensive Emergency
- Hypertensive Urgency: Severe BP elevation (>=180/>=120 mmHg) in an otherwise stable patient WITHOUT evidence of acute target organ damage. Managed with oral antihypertensive medications (e.g., Captopril, Clonidine, Labetalol, Amlodipine) with a goal of gradual BP reduction over 24 to 48 hours in the outpatient setting. Rapid IV reduction is contraindicated as it precipitates cerebral or myocardial ischemia.
- Hypertensive Emergency: Severe BP elevation WITH acute, life-threatening target organ damage:
- Neurologic: Hypertensive encephalopathy, acute ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage.
- Cardiovascular: Acute aortic dissection, acute coronary syndrome, acute cardiogenic pulmonary edema.
- Renal: Acute kidney injury with hematuria/proteinuria (malignant nephrosclerosis).
- Obstetric: Eclampsia or severe preeclampsia.
- Ophthalmologic: Grade IV hypertensive retinopathy (papilledema, flame hemorrhages, cotton-wool spots).
Blood Pressure Lowering Targets in Hypertensive Emergency
- General Rule: Reduce Mean Arterial Pressure (MAP) by maximum 20% to 25% within the first hour, then if stable, reduce BP toward 160/100-110 mmHg over the next 2 to 6 hours, and cautiously toward normal over the subsequent 24 to 48 hours in the ICU.
- CRITICAL EXCEPTIONS TO THE GENERAL RULE:
- Acute Aortic Dissection: Rapid, immediate reduction of Systolic BP to < 120 mmHg and Heart Rate < 60 bpm within 20 minutes using IV Esmolol/Labetalol + Nitroprusside.
- Acute Ischemic Stroke:
- Eligible for IV Thrombolysis (Alteplase/Tenecteplase): Lower BP carefully to < 185/110 mmHg before administering thrombolytic, and maintain < 180/105 mmHg for at least 24 hours post-thrombolysis.
- NOT receiving Thrombolysis/Thrombectomy: Permissive hypertension up to 220/120 mmHg is allowed to maintain penumbral perfusion, unless BP exceeds 220/120 mmHg (lower by 15% in first 24 hours) or other acute end-organ damage coexists.
- Eclampsia / Severe Preeclampsia: Rapidly reduce SBP to < 140 mmHg using IV Hydralazine, IV Labetalol, or oral Nifedipine, combined with IV Magnesium Sulfate for seizure prophylaxis.
Intravenous Antihypertensive Agents
- Nicardipine: Dihydropyridine CCB infusion (5-15 mg/h); excellent for encephalopathy, stroke, and renal failure.
- Clevidipine: Ultra-short-acting lipid-emulsion CCB (half-life 1-2 min; 1-32 mg/h); precise titration.
- Labetalol: Combined alpha-1 and non-selective beta blocker (1:7 alpha-to-beta ratio IV; 20 mg IV bolus followed by 40-80 mg q10min or infusion); safe in pregnancy and aortic dissection; avoid in acute decompensated HF or severe asthma.
- Esmolol: Ultra-short beta-1 blocker (onset 1 min; 500 mcg/kg load, then 50-300 mcg/kg/min); agent of choice for aortic dissection.
- Sodium Nitroprusside: Potent arterial and venous nitric oxide donor. Risk of Cyanide/Thiocyanate toxicity (altered mental status, metabolic lactic acidosis) with prolonged infusions (>48h), high doses (>2 mcg/kg/min), or renal/hepatic impairment.
- Nitroglycerin: Potent venodilator (reduces preload); drug of choice for acute pulmonary edema and ACS; headache and tachyphylaxis within 24-48h.
2. Dyslipidemia: 2018 AHA/ACC Guidelines & Statin Benefit Groups
Lipid management centers on ASCVD risk reduction through matching statin intensity to absolute risk, supplemented by targeted non-statin therapies.
The 4 Statin Benefit Groups
| Statin Benefit Group | Patient Population | Recommended Statin Intensity | Primary LDL-C Target / Goal |
|---|---|---|---|
| 1. Secondary Prevention: Clinical ASCVD | ACS, history of MI, stable angina, coronary revascularization, stroke/TIA, PAD | High-Intensity Statin (if age <=75y). Moderate-intensity if age >75y or intolerant | >=50% reduction in LDL-C and LDL-C < 55-70 mg/dL. If Very High-Risk ASCVD and LDL-C >=70 mg/dL on max statin, add Ezetimibe; add PCSK9 inhibitor if still >=70 mg/dL |
| 2. Severe Hypercholesterolemia | Baseline LDL-C >= 190 mg/dL (4.9 mmol/L) | High-Intensity Statin (no risk score calculation needed) | Target >=50% reduction in LDL-C. If LDL remains >=100 mg/dL on max statin, add Ezetimibe +/- PCSK9 inhibitor |
| 3. Diabetes Mellitus in Adults | Age 40 to 75 years with Type 1 or Type 2 DM and LDL-C 70–189 mg/dL | Moderate-Intensity Statin (High-Intensity if multiple ASCVD risk factors or 10-year risk >=20%) | Target 30-49% reduction in LDL-C (>=50% for high-intensity) |
| 4. Primary Prevention in Adults without DM | Age 40 to 75 years, LDL-C 70–189 mg/dL, stratified by 10-year Pooled Cohort Equations (PCE) risk | - Low Risk (<5%): Lifestyle<br/>- Borderline (5 to <7.5%): Moderate statin if risk enhancers present<br/>- Intermediate (7.5 to <20%): Moderate statin (target 30-49% reduction)<br/>- High Risk (>=20%): High-Intensity statin (target >=50% reduction) | If treatment decision is uncertain in Intermediate or Borderline risk, measure Coronary Artery Calcium (CAC) score |
Coronary Artery Calcium (CAC) Scoring in Decision-Making:
- CAC = 0: Statin therapy can be safely withheld or delayed (reassess in 3-5 years), unless the patient is a current cigarette smoker, has diabetes mellitus, or has a strong family history of premature ASCVD.
- CAC = 1 to 99 (or <75th percentile): Favors initiating moderate-intensity statin therapy.
- CAC >= 100 (or >=75th percentile): Strong indication for statin initiation regardless of estimated risk.
Statin Intensity Definitions
- High-Intensity Statins (Lowers LDL-C by >= 50%):
- Atorvastatin 40 to 80 mg daily
- Rosuvastatin 20 to 40 mg daily
- Moderate-Intensity Statins (Lowers LDL-C by 30% to 49%):
- Atorvastatin 10 to 20 mg daily
- Rosuvastatin 5 to 10 mg daily
- Simvastatin 20 to 40 mg daily
- Pravastatin 40 to 80 mg daily
- Lovastatin 40 mg daily
- Low-Intensity Statins (Lowers LDL-C by < 30%):
- Pravastatin 10 to 20 mg daily, Lovastatin 20 mg daily.
3. Non-Statin Pharmacotherapies
- Ezetimibe (10 mg daily): Inhibits Niemann-Pick C1-Like 1 (NPC1L1) protein at the enterocyte brush border, blocking dietary and biliary cholesterol absorption. Lowers LDL-C by 15-20%. First-line add-on to maximally tolerated statin therapy in secondary prevention and severe hypercholesterolemia (IMPROVE-IT trial).
- PCSK9 Inhibitors (Evolocumab 140 mg SC q2w / 420 mg monthly; Alirocumab 75-150 mg SC q2w): Fully human monoclonal antibodies that bind and neutralize Proprotein Convertase Subtilisin/Kexin type 9, preventing LDL receptor lysosomal degradation and dramatically upregulating hepatocyte LDL clearance. Lowers LDL-C by 50% to 60%. Proven to reduce cardiovascular death, MI, and stroke in very high-risk ASCVD (FOURIER and ODYSSEY OUTCOMES trials).
- Bempedoic Acid (Nexletol 180 mg daily): Inhibits ATP-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in hepatic cholesterol synthesis. Because it is a prodrug activated only in the liver (lacks activating enzyme in skeletal muscle), it does not cause statin-associated muscle symptoms (SAMS). Lowers LDL-C by 15-25% and reduces MACE in statin-intolerant patients (CLEAR Outcomes trial). Side effects: Hyperuricemia (gout), tendon rupture.
- Inclisiran (Leqvio): Small interfering RNA (siRNA) that inhibits intracellular PCSK9 translation in hepatocytes, administered subcutaneously on day 1, day 90, and then every 6 months. Lowers LDL-C by ~50%.
- Icosapent Ethyl (Vascepa 2 g PO BID with meals): Highly purified ethyl ester of eicosapentaenoic acid (EPA). Indicated for patients with established ASCVD or diabetes with >=2 additional cardiovascular risk factors who have fasting triglycerides 135–499 mg/dL despite statin therapy. Reduces cardiovascular death, MI, and stroke by 25% (REDUCE-IT trial). Side effects: Increased risk of atrial fibrillation/flutter and minor bleeding.
- Management of Severe Hypertriglyceridemia (Triglycerides >= 500 mg/dL): Primary objective is preventing acute pancreatitis. First-line therapy: Fibrates (Fenofibrate 54-160 mg daily; avoid Gemfibrozil with statins due to glucuronidation inhibition causing severe rhabdomyolysis), prescription Omega-3 fatty acids, strict dietary fat restriction (<15-20% of total daily calories), and complete alcohol abstinence.
Test Your Knowledge
A 62-year-old man with a history of a myocardial infarction 2 years ago (treated with a drug-eluting stent to the RCA) presents for routine follow-up. He is asymptomatic and adheres strictly to a Mediterranean diet. His current medications include Atorvastatin 80 mg daily, Aspirin 81 mg daily, and Metoprolol Succinate 50 mg daily. His blood pressure is 124/76 mmHg. Fasting lipid panel reveals: Total cholesterol 162 mg/dL, HDL-C 42 mg/dL, Triglycerides 130 mg/dL, and LDL-C 88 mg/dL. What is the most appropriate next step in lipid-lowering management according to the 2018 AHA/ACC guidelines?
A
B
C
D
Test Your Knowledge
A 52-year-old man presents to the emergency department with a severe headache, nausea, and visual blurring for the past 4 hours. His blood pressure is 224/132 mmHg. Funduscopic examination reveals bilateral papilledema, flame-shaped retinal hemorrhages, and cotton-wool spots. Laboratory tests show a serum creatinine of 2.4 mg/dL (baseline 1.0 mg/dL 6 months ago) with microscopic hematuria and red blood cell casts. ECG reveals left ventricular hypertrophy with strain pattern. Which of the following is the most appropriate blood pressure target during the first 1 to 2 hours of treatment?
A
B
C
D